Group 1 - The core point of the article is that Changfeng Pharmaceutical Co., Ltd. is preparing for an upcoming IPO in Hong Kong, with CITIC Securities acting as a joint sponsor [1][2] - The funds raised from the IPO will be allocated for various purposes, including ongoing R&D and clinical development of inhalation candidates, preclinical R&D for other pipeline projects, expansion and upgrading of production facilities, and general working capital [1] - Changfeng Pharmaceutical focuses on the research, production, and commercialization of inhalation technologies and drugs, targeting respiratory diseases and expanding into new therapeutic areas such as central nervous system diseases and anti-infection [2] Group 2 - The company has developed a diverse product portfolio aimed at a wide range of patients and medical specialties, with over 20 candidate products in development for major markets like China, the US, and Europe, as well as emerging markets in Southeast Asia and South America [2]
長風藥業:吸入技術及吸入藥物研發商通過港交所聆訊,或很快香港上市
Xin Lang Cai Jing·2025-09-23 00:31